Will Synairgen shares keep soaring on new Covid-19 treatment?

Synairgen shares are up 30% on Friday following positive trial data, with its new Covid-19 drug containing a protein that reduces the odds of developing severe symptoms and accelerates recovery.

  • Synairgen shares soar 30% on new Covid-19 treatment
  • The Southampton-based biotech company’s drug accelerates patients Covid-19 recovery
  • Synairgen stock is up 2150% year-to-date.

Shares in Synairgen are rallying sharply in today’s trade following positive trial data, with its new drug, known as SNG001, containing a protein that reduces the odds of developing severe symptoms of Covid-19.

The small scale trial results were published in the peer-reviewed Lancet journal, showing positive results in hospitalised patients.

Synairgen shares are up 30% to 130p at the time of publication, with the stock up 2150% year-to-date.

Synairgen’s new drug could accelerate Covid-19 recovery

The Southampton-based biotech company developed a naturally produced protein which helps the body fight viral infections. Synairgen, which was spun out of Southampton University said the drug ‘may have the potential as an inhaled drug to restore the lung's immune response and accelerate recovery from Covid-19’

‘The results confirm our belief that interferon beta, a widely known drug approved for use in its injectable form for other indications, may have the potential as an inhaled drug to restore the lung’s immune response and accelerate recovery from COVID-19,’ Professor Tom Wilkinson, Professor of Respiratory Medicine at the University of Southampton and Lead Author, said.

‘This pH neutral, inhaled interferon beta-1a formulation (SNG001) provides high, local concentrations of the immune protein which boosts lung defences rather than targeting specific viral mechanisms,’ he said.

‘This might carry additional advantages of treating COVID19 when it occurs alongside infection by another respiratory virus such as influenza or Respiratory Syncytial Virus that may well be encountered in the winter months,’ Wilkinson added.

Synairgen: technical analysis

Taking a look at the chart of Synairgen, the stock is down 50% from the summer peak, according to Victoria Scholar, presenter and market analyst at IG.

‘The stock was under pressure earlier this week on the back of Pfizer’s vaccine hopes,’ she said. ‘But today shares are bouncing back, with a gap higher combined with a buy signal from the RSI.’

‘Nonetheless, the stock still remains some way below its descending trendline that’s been in place since October,’ Scholar added. ‘Having broken back up above the 38.2% Fibonacci level, it is now on track to test the 50% fib level at 165.77.’

How to trade stocks with IG

Looking to trade Synairgen and other stocks? Open a live or demo account with IG and buy (long) or sell (short) shares using derivatives like CFDs in a few easy steps:

  1. Create an IG trading account or log in to your existing account
  2. Enter ‘Synairgen PLC’ in the search bar and select it
  3. Choose your position size
  4. Click on ‘buy’ or ‘sell’ in the deal ticket
  5. Confirm the trade

IGA, may distribute information/research produced by its respective foreign affiliates within the IG Group of companies pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the research is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, IGA accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact IGA at 6390 5118 for matters arising from, or in connection with the information distributed.

The information/research herein is prepared by IG Asia Pte Ltd (IGA) and its foreign affiliated companies (collectively known as the IG Group) and is intended for general circulation only. It does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. You should take into account your specific investment objectives, financial situation, and particular needs before making a commitment to trade, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit.

Please see important Research Disclaimer.

Seize a share opportunity today

Go long or short on thousands of international stocks.

  • Increase your market exposure with leverage
  • Get spreads from just 0.1% on major global shares
  • Trade CFDs straight into order books with direct market access

Live prices on most popular markets

  • Forex
  • Shares
  • Indices
liveprices.javascriptrequired
liveprices.javascriptrequired

Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.

liveprices.javascriptrequired

Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 20 mins.

The Momentum Report

Get the week’s momentum report sent directly to your inbox every Monday for FREE. The Week Ahead gives you a full calendar of upcoming key events to monitor in the coming week, as well as commentary and insight from our expert analysts on the major indices to watch.

For more info on how we might use your data, see our privacy notice and access policy and privacy webpage.

You might be interested in…

Find out what charges your trades could incur with our transparent fee structure.

Discover why so many clients choose us, and what makes us a world-leading provider of CFDs.

Stay on top of upcoming market-moving events with our customisable economic calendar.